Press Releases

RICHMOND, Va., Jul 25, 2002 (BW HealthWire) -- Insmed Incorporated (Nasdaq:INSM) announced today that in order to ensure the second quarter conference call is more accessible to all of our interested parties, the Company has rescheduled the call to take place on Tuesday, July 30 at 9:00am EST. The call was previously scheduled for Monday, July 29 at 8:00am. The live dial in number has changed to: 888/455-9642. 

To participate in the conference call dial 888/455-9642, password: INSMED. A live audio feed of the web cast can be accessed through the Investor Relations link on the Company's website: www.insmed.com. A telephonic replay of the call will be available for one week at 800/756-2729. A web replay of the call will be available through the Investor Relations website beginning at 11:00 a.m. 

About Insmed Incorporated 

Insmed Incorporated is a biopharmaceutical company focused on the development of drug candidates for metabolic diseases and endocrine disorders. The Company's product candidate, INS-1, is an orally active small molecule that restores insulin sensitivity to tissue. The Company is developing INS-1 for the treatment of type 2 diabetes and polycystic ovary syndrome, a significant women's health disorder. The company's product candidate, SomatoKine®, is being developed as an insulin sensitizer and growth promoting/anabolic agent. The drug is the recombinant form of human insulin-like growth factor-I (IGF-I) and its regulatory binding protein, IGFBP-3. SomatoKine is currently in clinical development for type 1 and type 2 diabetes, and growth hormone insensitivity syndrome (GHIS/Laron Syndrome). Further information is available at www.insmed.com. 



CONTACT: Insmed Incorporated, Richmond Baxter Phillips, III, 804/565-3041, bphillips@insmed.com